Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasis Top-line data from the 12-week double-blind trial expected by year-end 2025 Phase 1b trial designe ...
Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasisTop-line data from the 12-week double-blind ...
The following is a summary of “Impact of COVID-19 disease and vaccination on dermatological immune-mediated inflammatory ...
A real-world study in Spain finds faster improvements with induction therapy but highlights long-term drug survival ...
Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis: Princeton, New Jersey Tuesday, February 18, 2025, 1 ...
Biocon said that the European Commission has granted marketing authorisation in the European Union (EU) for Biocon Biologics' Ustekinumab biosimilar 'YESINTEK'.
Dr Grant said: “I recommend keeping a close eye on dry or cracked skin as it can be a telltale sign of psoriasis. Dry skin ...
Daily Express US on MSN3d
Doctor shares telltale signs of contagious skin condition - one is 'intense'A doctor has explained how to distinguish between a common skin condition that millions have and a more worrying contagious ...
CNET on MSN5d
How to Spot an Unhealthy Gut and What to Do About ItA healthy gut is essential for overall well-being, but how can you tell if yours is in top shape or needs a reset? It al ...
Roflumilast demonstrated effectiveness and safety in treating psoriasis, with added benefits for patients with comorbidities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback